Viral vectors are highly efficient vehicles for gene delivery into a specific cell type or tissue for an array of research purposes.
Our viral vector technologies and services have empowered innovators in cell therapy, gene therapy, and vaccination to successfully advance their therapies from preclinical research through development and ultimately to market.
How Revvity can support you
Regardless of the field of application, viral vector-based therapies go through a discovery phase where proof-of-concept is established, vectors are optimized, and safety and efficiency studies of the lead vector candidate are completed.
Revvity’s gene delivery team, where SIRION Biotech’s expertise lives on, has deep know-how in viral vector development and manufacturing with 20 years of experience in the field. We offer a comprehensive viral vector offering, covering adeno-associated viruses (AAVs), lentiviruses (LV) and Adenoviruses (AVs) for early discovery and preclinical research stages.
Our gene delivery portfolio includes:
- Viral vector development and manufacturing services - leverage our team’s deep experience and advanced technology to help accelerate the process and find the right balance of flexibility, scalability, and quality for your viral vectors.
- LentiBOOST™ lentiviral transduction enhancer provides improved transduction efficiency to help reduce manufacturing costs and improve the effectiveness of your cell therapy.
- AAV capsid evolution and nanobody targeting technologies and services which can deliver improved performance from your AAV vectors.
- A range of viral vector technologies across AAV, LV and AV platforms to help improve vector efficacy, quality, and yields.
For research use only. Not for use in diagnostic procedures.
